Neuroblastoma - 49 Studies Found
| Active, not recruiting |
: A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma : Neuroblastoma : 2013-02-21 : Biological: Activated T lymphocyte intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour. |
| Completed |
: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma : Refractory Neuroblastoma : 2025-11-25 : The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimer |
| Completed |
: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma : Neuroblastoma : 2025-11-25 : The cell dose will be based on the subject's body weight.Subjects will receive a single infusion of third party, ex vivo expanded, froze |
| Completed |
: A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma : Neuroblastoma : 2025-11-25 : Comprised of the immunological adjuvant OPT-821 (QS-21) |
| Completed |
: Open-Label Study of 18F-mFBG for Imaging Neuroblastoma : Neuroblastoma : 2025-11-25 : Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent |
| Completed |
: High Dose Chemotherapy and Autologous Transplant for Neuroblastoma : Neuroblastoma : 2025-11-25 : Carboplatin intravenously (IV), 425 mg/m2/dose (or if ? 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretranspl |
| COMPLETED |
: Biomarkers of Renal Dysfunction in Neuroblastoma Survivors : Neuroblastoma Survivors : 2025-11-25 : The urine collected from the first morning void will be used to assess urine creatinine and microalbumin.The fresh urine specimen will be analyz |
| COMPLETED |
: Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma : Neuroblastoma : 2025-11-25 : chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight<70kg) or 1500mg/m^2/day (for pat |
| COMPLETED |
: A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma : Neuroblastoma : 2025-11-25 : Day 1: hu3F8 infused iv over ~30 to 90 minutes.Day 3: hu3F8 infused iv over ~30 to 90 minutes.Day 5: hu3F8 infused iv over ~30 to 90 minut |